Page 14 - Lupin

Launches, base biz expansion tonic for Dr Reddy's double-digit growth

While the company's bottom line grew 10.5% annually over the 2016-17 through 2021-22 (FY22) period, it is expected to register thrice that growth rate over next two years, observes ICICI Securities

Investors poorer by Rs 7 trn as Sensex crashes 1,416pts; Nifty holds 15,800

CLOSING BELL: The Nifty IT index plunged 6 per cent on the NSE today after global brokerage JPMorgan downgraded the sector to "underweight".

Lupin slips 9%, hits 2-year low on disappointing March quarter results

Lupin's performance was skewed on revenues front amid US and India posting lower than expected sales while RoW and South Africa saw better than anticipated traction this quarter.

Stocks to Watch: ITC, Lupin, Ruchi Soya, Manappuram Finance, JSW, Biocon

Stocks to Watch: The US markets suffered the biggest one-day sell-off in almost two years -Investors worry about inflation and its impact on earnings and prospects for monetary policy tightening

Lupin logs net loss of Rs 512 cr in Q4 on rising costs, impairment expense

Quarter was challenging due to 'headwinds in the US on account of price erosion', says company.

Rejuvenating Cipla: After global expansion, acquisitions on cards

Having consolidated its presence across geographies, the pharma major is looking at acquisitions

Lupin receives USFDA approval for anti-depressant drug

It is the generic equivalent of Pristiq, extended-release tablets, 25 mg of PF PRISM C.V, it added

Lupin launches generic contraceptive drug Merzee capsules in US

Slayback had earlier launched this product in the US in February 2021

Lupin inks licensing pact with Alvion to market drugs in Southeast Asia

The Mumbai-based company said it is committed to providing affordable treatment options to healthcare providers and patients

Markets start FY23 with solid gains; Sensex jumps 708pts, Nifty tops 17,650

CLOSING BELL: Sectorally, the Nifty PSU Bank index jumped 4 per cent on the bourses with Union Bank, Bank of India, Canara Bank, and Bank of Maharashtra adding over 4 per cent each

Stocks to Watch: Hero Moto, Vedanta, Lupin, Future Retail, ONGC, Tech M

The SGX Nifty futures were quoting at 17,431 levels at 7:30 am, hinting at a gap-down start of 100 points on the Nifty50.

Lupin's New Jersey facility gets 13 US FDA observations

The observations do not, however, imply any restriction on supplies

Stocks to Watch: Paytm, Gail, Maruti, Hindalco, SAIL, Lupin, Welspun India

Paytm is likely to be in focus after RBI's ban on fresh onboarding of customers to its arm Paytm Payments Bank with immediate effect over the weekend.

Lupin gets USFDA approval to market anti-epilepsy drug in US market

Drug firm Lupin on Friday said it has received approval from the US health regulator to market its anti-epilepsy drug Vigabatrin for Oral Solution in the American market.

Stocks to Watch: Lupin, Jindal Steel, Wipro, Future Group, Tata Steel Long

Lupin may be in focus as it has launched its first Reference Laboratory in East India in Kolkata.

Lupin signs Mary Kom as brand ambassador for its Shakti campaign

Homegrown pharma major Lupin Ltd on Monday said it has signed six-time world boxing champion and Olympics bronze medallist Mary Kom as brand ambassador for its Shakti campaign

Lupin gets FDA nod to market Efinaconazole topical solution in US

Drug major Lupin on Thursday said it has received approval from the US health regulator to market Efinaconazole topical solution, used to treat fungal toenail infections, in the American market

Lupin launches generic medication, to be manufactured in Nagpur, in US

Drug maker Lupin on Tuesday said it has launched Sevelamer Hydrochloride tablets (800 mg), used to treat hyperphosphatemia in patients with chronic kidney disease, in the US market

Sensex dips for 3rd day, slips 59 pts; Ambuja Cement falls 6%, HDFC up 1%

On the sectoral front, key indices ended in the negative zone led by the Nifty Realty index (down 1.2 per cent) and the Nifty Pharma index (down 0.8 per cent).

Lupin receives USFDA approval for antibiotic Solosec

Lupin Ltd on Thursday said it has received approval from the US health regulator for its supplemental New Drug Application (sNDA) for usage of its antibiotic Solosec.